# Real World Effectiveness of Eptinezumab in Participants With Migraine

> **NCT05284019** · PHASE4 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 32 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** Erenumab
- **DRUG:** Onabotulinumtoxin-A
- **DRUG:** Fremanezumab
- **DRUG:** Galcanezumab

## Key facts

- **NCT ID:** NCT05284019
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-04
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-04-14
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The study was terminated due to enrolment challenges.
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284019, "Real World Effectiveness of Eptinezumab in Participants With Migraine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05284019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*